BioCentury
ARTICLE | Finance

Belgium’s Bioqube earmarking some of planned €100M fund for ‘de-risking’ projects

With first €60M close, Bioqube seeks mix of traditional early-stage deals and asset-centric investments

June 10, 2020 5:06 AM UTC

Four years after its launch as the manager of companies in J&J’s Belgian incubator, Bioqube Ventures has raised €60 million toward its first independent venture fund earmarked for European start-ups operating in its sweet spots -- with the pharma serving as one of two strategic LPs.

Managing partners Nico Vandervelpen and Debora Dumont told BioCentury that Bioqube Factory Fund I will aim to invest in two key areas: “classical” early-stage biotech deals, and assets or projects that require additional de-risking in order to progress to the next stage...